期刊文献+

凝血因子Ⅷ研究和应用的现状与前景 被引量:5

Status and prospects of research and development of coagulation factor Ⅷ
暂未订购
导出
摘要 基因重组型凝血因子Ⅷ(rFⅧ)代替血浆来源的FⅧ(pdFⅧ)治疗血友病甲是血友病治疗史上的一次革命,但仍存在难以令人完全满意的地方,而目前研制的二代rFⅧ即B区缺失型FⅧ具有的优点弥补了野生型rFⅧ的不足,必将促使患者的选择由pdFⅧ彻底转向rFⅧ。 The treatment of hemophilia A with recombinant coagulation factorⅧ(rFⅧ)replacing plasma-derivedⅧ(pdFⅧ)has revolutionized hemophilia A cure.The full-length rFⅧproducts,however have some disadvantages.Second gener-ation,B-domain-deleted rFⅧhas some obvious advantages and the potential to meet the cure needs.The patients would rather choice the rFⅧthan the pdFⅧfor the treatment of hemophilia A in the future.
作者 赵艳华
出处 《生物技术通讯》 CAS 2002年第6期473-475,共3页 Letters in Biotechnology
关键词 凝血因子Ⅷ 应用 现状 血浆来源 重组型 研究进展 血友病 coagulation factorⅧ plasma-derived coagulation factorⅧ recombinant coagulation factorⅧ
  • 相关文献

参考文献14

  • 1Hoyer LW. The factor Ⅷ complex: structure and function[J]. Blood, 1981,58:1
  • 2Gitschier T, Wood WI, Goralka TM, et al. Characterization of the human factor Ⅷ gene[J]. Nature, 1984,312:326
  • 3White GC Ⅲ, McMillam CW, Kingdon HS, et al. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia[J]. N Engl J Med, 1989,320:166
  • 4Brackmann HH, Oldenburg J, Eis-Hubinger AM, et al. Hepatitis A virus infection among the hemophilia population at the Bonn Hemophilia Center[J]. Vox Sang, 1994,67(Suppl 1):3
  • 5Lawlor E, Johnson Z, Thornton L, et al. Investigation of an outbreak of hepatitis A in Irish haemophilia A patients[J]. Vox Sang, 1994,67(Suppl 1):18
  • 6Soucie JM, Robertson BH, Bell BP, et al. Hepatitis A virus infections associated with clotting factor concentrate in the United Stares[J]. Transfusion, 1998,38:573
  • 7Franco AC, Ciesta LJF, Torres FJ, et al. Parvovirus B19 infection in patients with congenital blood coagulation disorders [J]. Med Clin, 1997,108:641
  • 8Santagostino E, Mannucci PM, Gringeri A, et al. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization[J]. Transfusion, 1997,37: 517
  • 9Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor Ⅷ from recombinant DNA clones[J]. Nature, 1984,312:330
  • 10Eaton DL, Wood WI, Hass PE, et al. Construction and characterization of an active factor Ⅷ variant lacking the central one-third of the molecule[J]. Biochem J, 1986;25:8342

同被引文献69

  • 1朱永明,余自强,吴竞生,孙萍.二步法病毒灭活的凝血因子Ⅷ浓缩剂临床疗效及药动学观察[J].临床输血与检验,2001,3(4):11-13. 被引量:1
  • 2EMEA警告重组人凝血因子Ⅶ产生抗体的风险[J].中国药物警戒,2006,3(3):187-187. 被引量:2
  • 3毛平,王鸿利.遗传性血浆凝血因子缺陷的出血[M]//邓家栋,杨崇礼,杨天楹,等.临床血液学.上海:上海科学技术出版社,2001:1393-1407
  • 4李家增,季林祥.凝血障碍[M]//刘隽湘.输血疗法与血液制剂.北京:人民卫生出版社,1996:93-109
  • 5刘隽湘,张天仁.病毒灭活[M]//刘隽湘.输血疗法与血液制剂.北京:人民卫生出版社,1996:244-252
  • 6王学锋,王鸿利.凝血因子Ⅷ浓缩剂的临床应用[M]//王鸿利,高峰.血浆和血浆蛋白制品的临床应用.上海:上海科技出版社,2002:66-72
  • 7WFH.2006 WFH global survey summary[ OL]. [ Last updated: 2008-01 ]. http ://www. wfh. org/2/4/4_4_Link10_WFH-News_Global-Survey2006, htm
  • 8SFSA.国家四点措施促进凝血八因子生产年底200万上市[OL].2007[2007-12-12].http://www.gov.cn/wszb/zhibo183/content_832023.htm
  • 9张天仁.凝血因子Ⅷ浓制剂[M]//刘隽湘.输血疗法与血液制剂.北京:人民卫生出版社,1996:214-220
  • 10WFH. Registry of clotting factor concentrates[OL]. [ Last updated: 2008-01 ]. http://www. wfh. org/2/docs/Publications/ Treatment_Products/Monographs/FF6_ Registry_7ed_2006. pdf.

引证文献5

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部